Dernières nouvelles pour Illumina (NASDAQ:ILMN) Stock

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Inc

Illumina Inc COM-WHEN ISSUED

News

ILMN

MYGN

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

Illumina Highlights TruSight Oncology Portfolio

Morgan Stanley analyst Tejas Savant reinstates Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and announces $156 price target.

Price Target

Initiation

Analyst Ratings

Morgan Stanley Reinstates Equal-Weight on Illumina, Announces $156 Price Target

Stephens &amp; Co. analyst Mason Carrico maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and raises the price target from $170 to $184.

Stephens & Co. Maintains Overweight on Illumina, Raises Price Target to $184

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and lowers the price target from $195 to $185.

Piper Sandler Maintains Overweight on Illumina, Lowers Price Target to $185

Baird analyst Catherine Ramsey maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and raises the price target from $124 to $139.

Baird Maintains Neutral on Illumina, Raises Price Target to $139

TD Cowen analyst Dan Brennan maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and raises the price target from $166 to $177.

TD Cowen Maintains Buy on Illumina, Raises Price Target to $177

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes <a href="https://www.benzinga.com/topic/2024-election">for the 47th president.</a>
Betting markets leaned slightly toward Donald Trump, with CFTC-regulated Kalshi placing Trump's win probability at 56% compared to Kamala Harris's 44%.
National polls show a close contest, with the latest New York Times/Siena College poll indicating both candidates tied at 48% in the popular vote.
The S&amp;P 500 climbed 1.2%, while the tech-focused Nasdaq 100 surged 1.5%, marking its strongest one-day increase in nearly a month. 
All 11 sectors of the S&amp;P 500 experienced gains, with consumer discretionary stocks outperforming. Small caps also joined the rally, with the Russell 2000 index gaining 1.1%.
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) led the S&amp;P 500, with shares soaring after the artificial intelligence company surpassed quarterly earnings estimates and provided strong guidance.
In macroeconomic news, U.S. services sector activity hit over two-year highs <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41750522/us-services-sector-gauge-rises-more-than-expected-to-over-2-year-highs-as-employm">in October, outperforming expectations</a>.
Treasury yields increased by 5 basis points, while the dollar declined for a second consecutive session.
Gold edged up 0.3%, hovering near record highs, and oil prices gained 1.2% after a 3.2% surge on Monday.
Crypto sentiment was strong as well, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumping 4.5% to over $70,000 and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) spiking 12%.
Read also: <a href="https://www.benzinga.com/markets/24/11/41741466/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,259.62</td>
<td>1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,779.38</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.40</td>
<td>1.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,191.93</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $575.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.9% to $421.79.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.4% to $492.61.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $222.47.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.7%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, up 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), up 4.8%</li>
<li>Palantir Technologies Inc., up 22.8%</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), down 6.8%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), down 1.6%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), down 2.3%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), down 0.5%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), up 6.2%</li>
<li>Emerson Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), up 6.8%, </li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), up 3.9%, </li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), up 8.8%, </li>
<li>Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>), 4.7%,</li>
<li>YUM! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), up 2.5%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Politics

Economics

Markets

Tech

ETFs

$BTC

$DOGE

SPDR Dow Jones Industrial Average ETF Trust

FANG

NXPI

PLTR

TRGP

VRTX

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?

UBS analyst John Sourbeer maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and raises the price target from $133 to $145.

UBS Maintains Neutral on Illumina, Raises Price Target to $145

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and raises the price target from $252 to $254.

RBC Capital Maintains Outperform on Illumina, Raises Price Target to $254

JP Morgan analyst Julia Qin maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and raises the price target from $125 to $140.

JP Morgan Maintains Neutral on Illumina, Raises Price Target to $140

Citigroup analyst Patrick Donnelly maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Buy and raises the price target from $155 to $190.

Citigroup Maintains Buy on Illumina, Raises Price Target to $190

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Equal-Weight and raises the price target from $135 to $145.

Barclays Maintains Equal-Weight on Illumina, Raises Price Target to $145

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and raises the price target from $130 to $145.

Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $145

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) raises FY2024 Adj EPS guidance from $3.80-3.95 to $4.05-4.15 vs $3.82 analyst estimate. Narrows FY2024 sales outlook from $4.30 billion-4.35 billion to $4.30 billion vs $4.35 billion estimate.

Guidance

Illumina Raises FY2024 Adj EPS Guidance from $3.80-3.95 to $4.05-4.15 vs $3.82 Est; Narrows FY2024 Sales Guidance from $4.30B-4.35B to $4.30B vs $4.35B Est

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) sees Q4 sales of $1.070 billion vs $1.08 billion estimate.

Illumina Sees Q4 Sales $1.070B vs $1.08B Est

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $0.88 by 29.55 percent. The company reported quarterly sales of $1.080 billion which beat the analyst consensus estimate of $1.079 billion by 0.08 percent. This is a 3.49 percent decrease over sales of $1.119 billion the same period last year.

Earnings

Earnings Beats

Illumina Q3 2024 Adj. EPS $1.14 Beats $0.88 Estimate, Sales $1.080B Beat $1.079B Estimate

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Mid Cap

ALAB

HOLX

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has risen 23.33% since its last report. The company recently reported that it has 6.78 million shares sold short, which is 4.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730731623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 5.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Illumina's Recent Short Interest

<ul>
<li>New, groundbreaking technology delivers Illumina's most comprehensive genome yet; early results from Broad Clinical Labs demonstrate a highly simplified workflow, ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information &nbsp;</li>
<li>Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology</li>
</ul>
SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics (ASHG)&nbsp;Annual Meeting next week in Denver. The latest details will be presented alongside new data from key opinion leaders in next-generation sequencing (NGS), illustrating the potential impact of Illumina's emerging innovations.

Biotech

General

Illumina Announces That It Will Present Updates On Several Key Innovations In Whole-Genome Sequencing, Proteomics, And Single-Cell Technology At The American Society Of Human Genetics Annual Meeting

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Nvidia initiated, Airbnb downgraded: Wall Street's top analyst calls

ARKK's holdings ranked by SA Quant Grades

Illumina coverage resumed at equal weight by Morgan Stanley

Short + Long Strategies And What Alpha's Really All About

As healthcare rapidly advances, AI-driven technologies present compelling investment opportunities. Hence, investors might find promising potential in fundamentally solid healthcare stocks like Intuitive Surgical (ISRG), Illumina (ILMN), and Teladoc Health (TDOC). Keep reading... As digital transformation accelerates in healthcare, the adoption of artificial intelligence is on the rise, driven by advanced technologies, clinical research innovations, and demand for personalized care.
Leading the charge in AI-driven healthcare innovation, IIntuitive Surgical, Inc. (<a href="https://stocknews.com/stock/ISRG/">ISRG</a>), Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>), and Teladoc Health, Inc. (<a href="https://stocknews.com/stock/TDOC/">TDOC</a>) are revolutionizing the industry with cutting-edge technologies that promise to reshape patient care and medical precision. So investors could scoop up the stocks to reap the benefits.
The healthcare industry's growing reliance on digital technology is accelerating global adoption of AI, enhancing patient care and reducing costs. This growth is fueled by factors such as rising chronic illnesses, an aging population, and the demand for personalized medicine. The global AI in healthcare market is projected to grow to approximately $355.78 billion by 2032, indicating a robust <a href="https://www.towardshealthcare.com/insights/ai-in-healthcare-market#:~:text=The%20global%20AI%20in%20healthcare%20market%20is%20estimated,clinical%20research%20and%20rising%20demand%20for%20customized%20healthcare.">CAGR of 37.7%</a>.
Additionally, AI and machine learning are being integrated to improve patient outcomes and enable early diagnosis, especially for neurodegenerative diseases. Advances in AI processing power have further propelled the use of algorithms in healthcare.
Considering these conducive trends, let's examine the healthcare stocks in detail.
Intuitive Surgical, Inc. (<a href="https://stocknews.com/stock/ISRG/">ISRG</a>)
ISRG develops innovative minimally invasive surgical and diagnostic systems, including the da Vinci Surgical System and Ion endoluminal system. Supporting global healthcare providers, the company offers advanced instrumentation, comprehensive training, and robust service infrastructure for enhanced surgical performance and patient care.
During the fiscal third quarter that ended September 30, 2024, ISRG's total revenue increased 17% year-over-year to $2.04 billion. In addition, the company's non-GAAP net income and EPS came in at $669.10 million and $1.84 per share, up 27.7% and 26% over the prior-year quarter, respectively.
Analysts expect ISRG's EPS and revenue for the fourth quarter, ending in December 2024, to increase 9.5% and 14.1% year-over-year to $1.75 and $2.20 billion, respectively. It surpassed the Street EPS and revenue estimates in each of the trailing four quarters, which is promising.
Over the past year, the stock has gained 84.1% to close the last trading session at $507.42. It soared 51.3% year-to-date.
ISRG's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
ISRG has an A grade in Sentiment. It is ranked #72 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry.
Beyond what we have stated above, we have also given ISRG grades for Growth, Stability, Value, Momentum, and Quality. Get all the ISRG's ratings <a href="https://stocknews.com/stock/ISRG/ratings/">here</a>.
Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN delivers advanced sequencing and array-based solutions for genetic and genomic analysis worldwide. Through its Core Illumina and GRAIL segments, it offers a range of instruments, consumables, and services, including whole-genome and targeted sequencing, noninvasive prenatal testing, and the Galleri multi-cancer early detection test.
On August 27, 2024, ILMN received FDA approval for its TruSight&#x2122; Oncology (TSO) Comprehensive test, along with companion diagnostics for targeted therapies. This test analyzes over 500 genes to identify biomarkers in solid tumors, potentially benefiting patients with NTRK gene fusions and RET fusion-positive NSCLC.
In the fiscal third quarter ended on September 29, 2024, ILMN's total revenues amounted to $1.08 billion. Its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingmargin.asp">operating margin</a> went up 22.6% from the year-ago value of 8.3%. Moreover, its EPS stood at $4.42 compared to a loss of $4.77 in the prior-year quarter.
Street expects ILMN's EPS for the fourth quarter of 2024, ending on December 31, 2024, to increase 561.6% year-over-year to $0.93. It surpassed the consensus revenue estimates in all of the trailing four quarters.
The stock climbed 35.3% year-to-date and 9.6% over the past year to close the last trading session at $152.76.
ILMN's POWR Ratings reflect strong prospects. The stock has an overall rating of B, translating to a Buy in our proprietary rating system.
It has a B grade for Growth, Sentiment, and Quality. It is ranked #32 out of 328 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
To access ILMN's Stability, Momentum, and Value ratings, click <a href="https://stocknews.com/stock/ILMN/ratings/">here</a>.
Teladoc Health, Inc. (<a href="https://stocknews.com/stock/TDOC/">TDOC</a>)
Teladoc Health, Inc. delivers comprehensive virtual healthcare services globally through its Teladoc Health Integrated Care and BetterHelp segments. It offers a wide range of virtual medical services, chronic condition management, and mental health support, including online counseling via its Teladoc, Livongo, and BetterHelp brands.
TDOC's revenue was $640.51 million in the third quarter, which ended on September 30, 2024. The non-GAAP gross margin was 71.9%, and the cash flow from operations improved 4.4% from the year-ago value to $110.20 million.
Street expects TDOC's revenue to amount to $2.57 billion in the fiscal year ending December 2024. It surpassed the consensus EPS estimates in each of the trailing four quarters.
TDOC's bright prospects are apparent in its POWR Ratings. It has a B grade for Value. Within the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry, it is ranked #35 out of 62 stocks.
Click <a href="https://stocknews.com/stock/ISRG/ratings/">here</a> to see TDOC's ratings for Growth, Stability, Sentiment, Momentum, and Quality.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ISRG shares were trading at $516.49 per share on Tuesday afternoon, up $9.07 (+1.79%). Year-to-date, ISRG has gained 53.10%, versus a 22.17% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/isrg-ilmn-tdoc-3-healthcare-stocks-innovating-with-ai/>3 Healthcare Stocks Innovating with AI</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks Innovating with AI

Fidelity Mid-Cap Stock Fund Q3 2024 Review

Cantor Fitzgerald's "Tracker Quants" laid out its forecasted changes for the upcoming Nasdaq 100 Index review. Nasdaq will implement its annual reb...

Cantor sees six changes to Nasdaq 100 Index in December rebalance

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

Illumina (ILMN) will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profilin...

Illumina releasing expanded version of TruSight Oncology portfolio

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

AAPL

ABBV

ABNB

ACGL

ACGLN

ACGLO

ACHR

ADPT

AFGB

AFGC

AFGD

AFGE

ALGM

AMZN

ARGX

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

AVTR

AXON

BCUCF

BCUCY

BEAM

BRKR

CDNS

CERS

CEVA

COIN

CRSP

CURI

CURIW

DKNG

ENGH

EXAS

FBIN

FIVN

GTLS

HOOD

IHRT

INTC

ISRG

LCID

MDXH

MRNA

MRVL

MSTR

NTLA

NTRA

NVDA

NWTN

NWTNW

OKTA

PACB

PATH

PFGC

PINS

PRME

QCOM

QRVO

RBLX

RMBS

ROKU

ROST

RVTY

RXRX

SHOP

SMCI

SNDR

SNPS

SOFI

SWKS

TDOC

TSLA

TWLO

TWST

VCYT

VERV

XPRO

Press Releases

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

European Court of Justice rules in favor of Illumina in jurisdictional appeal

Charles Dadswell to step down as General Counsel, Illumina initiates search for successor

Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers

Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024

Illumina To Webcast Upcoming Investor Conferences

Illumina announces expansion of TruSight Oncology portfolio

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Comments

Illumina

Actualités

Dernières nouvelles pour Illumina (NASDAQ:ILMN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL